This article is from the WeChat public account: Enlarged light (ID: guokr233) , author: Li Tuo, from the title figure: Figure worm
November 21, 2019, Eastern time, a precision medical company called Pangene Genes submitted a prospectus to the US Securities and Exchange Commission; on December 17, another company named Burning Stone Medicine, There is also news that it will be listed next year.
If it goes well, the precision stocks in precision medicine will achieve “two blossoms”.
It is worth noting that these two Chinese companies are investing heavily in research on the technology of early screening of cancer genes.
But to the general public, early screening of cancer genes is still a very strange story-what is their principle? What troubles do these companies have?
The world is facing a growing cancer threat, which may be bad news. New research shows that among the 95 cancer categories in 195 countries from 2007 to 2017, the incidence of cancer is increasing in almost all countries, and more than a quarter of people are at risk of cancer [1] .
The case that has recently attracted attention is the news that 33-year-old Shougang Men’s Basketball captain Ji Xun died of lung cancer. According to media reports, when Ji Ji was diagnosed with cancer, he was already in the middle and advanced stages of lung cancer-this is a noteworthy detail. For most cancer types, “early detection and early treatment” will lead to a more optimistic prognosis.
Evidence from the data: Cancer Statistics 2019 points out that in the past two decades, early screening and timely treatment have caused a decline in the mortality rate of various cancers in the United States.
Men ’s lung cancer mortality rate has decreased by 48% (1990 ~ 2016) ;
Lung cancer death rate among women has dropped by 23% (2002 ~ 2016) ;
Breast cancer mortality rate drops by 40% (1989 ~ 2016) ;
Prostate cancer mortality decreased by 51% (1993 ~ 2016) ;
The mortality of rectal cancer has decreased by 53%. (1970 ~ 2016) .
In addition to declining mortality, the cost of early detection is also lower. There is a cancer early screening practitioner who told the Magnifying Lamp team (public ID: guokr233 ), taking liver cancer as an example, it was detected early, As long as a resection operation costs 30,000 to 50,000 yuan (including post-care costs) , the expenditure for intermediate and advanced liver cancer is greatly increased. The cost is about 280,000 / year, and once resistance develops, you need to find new targets and change medicines.
From the perspective of patient experience and financial burden, it is the general trend for cancer diagnosis and treatment to move forward, and “early screening” is becoming increasingly important.
To date, many technologies have been developed or are being tested for early cancer screening, including:
Mo target film